Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Tibulizumab · ZB-106, LY-3090106

Bispecific antibody · Antagonist of BAFF (TNFSF13B) and IL-17 (IL17A) · developed by Zura Bio

Phase 2 Most advanced trial

ZURA Developer

2 Registered trials

What is Tibulizumab?

Tibulizumab is a bispecific antibody that binds both BAFF and IL-17. It is being studied in systemic sclerosis and hidradenitis suppurativa.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ZB-106, LY-3090106
Drug type: Bispecific antibody
Targets: BAFF (TNFSF13B), IL-17 (IL17A)
Mechanism: Antagonist of BAFF (TNFSF13B) and IL-17 (IL17A)
Therapy area: Dermatology
Developer: Zura Bio Inc (ZURA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 42HQ15W1ZF

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06993610	Phase 2	Hidradenitis Suppurativa (HS)	Active not recruiting	ZURA
NCT06843239	Phase 2	Systemic Sclerosis (SSc)	Active not recruiting	ZURA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hidradenitis Suppurativa (HS)SclerodermaSystemic Sclerosis (SSc)

Other drugs acting on TNFSF13B / IL17A

Atacicept FDA approved Povetacicept Phase 2/3 Telitacicept Phase 3

Sources

ClinicalTrials.gov NCT06993610

Updated Oct 3, 2026. Something wrong or missing? Report it on the ZURA page.

Follow ZURA, the company behind Tibulizumab

See ZURA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZURA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z